Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*

References

• Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ (Clinical research ed.) 2008;337:1.
   Google Scholar
• Roth G, Fihn S, Mokdad A, et al. WHO | High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bull World Health Organ. 2011;89:92–10.
   Web of Science ®Google Scholar
• National Center of Public Health and Analyses (Национален център по обществено здраве и анализи). Morbidity of population [Internet]. [cited 2016 Feb 15]. Available from: http://ncphp.government.bg/en/morbidity-2.html
   Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.
   PubMed Web of Science ®Google Scholar
• Levine DA, Davydow DS, Hough CL, et al. Functional disability and cognitive impairment after hospitalization for myocardial infarction and stroke. Circ Cardiovasc Qual Outcomes. 2014;7:863–871.
   PubMed Web of Science ®Google Scholar
• De Smedt D, Clays E, Annemans L, et al. Health related quality of life in coronary patients and its association with their cardiovascular risk profile: results from the EUROASPIRE III survey. Int J Cardiol. 2013;168:898–903.
   PubMed Web of Science ®Google Scholar
• Wilkins E, Wilson L, Wickramasinghe K, et al. European Cardiovascular Disease Statistics 2017 [Internet]. European Heart Network. 2017 [cited 2017 Mar 1]. Available from: http://www.ehnheart.org/cvd-statistics.html
   Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.
   PubMed Web of Science ®Google Scholar
• Leeper NJ, Ardehali R, deGoma EM, et al. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation. 2007;116:613–618.
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–1701.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists Collaboration (CTTC). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. Elsevier Ltd. 2010;376:1670–1681.
   Web of Science ®Google Scholar
• Cholesterol Treatment Trialists Collaboration (CTTC). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
   Web of Science ®Google Scholar
• Cholesterol Treatment Trialists Collaboration (CTTC). Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet. 2015;385:1397–13405.
   Web of Science ®Google Scholar
• Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5:S1–S8.
   PubMed Web of Science ®Google Scholar
• Benn M, Watts GF, Tybjaerg-Hansen A, et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metabolism. 2012;97:3956–3964.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. Massachusetts Medical Society. 2017.
   Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373–2384.
   Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331–340.
   PubMed Web of Science ®Google Scholar
• Gandra S, Villa G, Fonarow G, et al. Cost-effectiveness of LDL-c lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39:313–320.
   PubMed Web of Science ®Google Scholar
• Villa G, Lothgren M, Kutikova L, et al. Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain. Clin Ther. Elsevier. 2017;39:771–786.e3.
   PubMed Web of Science ®Google Scholar
• Toth PP, Danese M, Villa G, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ . Taylor Francis. 2017;20:555–564.
   Web of Science ®Google Scholar
• Gray AM. Applied methods of cost-effectiveness analysis in healthcare. Oxford, New York: Oxford University Press; 2010.
   Google Scholar
• Wei C-Y, Quek RGW, Villa G, et al. A systematic review of cardiovascular outcomes-based cost-effectiveness analyses of lipid-lowering therapies. PharmacoEconomics. 2017;35:297–318.
   PubMed Web of Science ®Google Scholar
• Ministry of Health (Министерство на здравеопазването). Ordinance No. 9 from 01.12.2015 for the conditions and order for executing health technology assessment [Internet]. 2015. [cited 2016 Feb 15]. Available from: http://www.mh.government.bg/media/filer_public/2015/12/11/naredba9-1-12-2015.pdf
   Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias [Internet]. Marie-Therese, Badimon, Lina Funck-Brentano, Christian Agewall, Stefan Barón-Esquivias, Gonzalo Borén, Jan Bruckert, Eric Cordero, Alberto Corsini, Alberto Giannuzzi, Pantaleo Gueyffier, François Krstačić, Goran Lettino, Maddalena Lionis, Christos Lip, G C, editor Eur Heart J. 2016. DOI:10.1093/eurheartj/ehw272
   Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90a.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 2014;129:S1–S45.
   Google Scholar
• Kotseva K. EUROASPIRE IV - Principal results: medical risk factors. Presented at the ESC Congress 2013, August 31–September 4, Amsterdam; 2013.
   Google Scholar
• De Backer G, Besseling J, Chapman J, et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis. 2015;241:169–175.
   PubMed Web of Science ®Google Scholar
• Cooper A, Nherera L, Calvert N, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008. p. 1–241.
   Google Scholar
• Jernberg T, Held C, Johanson P, et al. Annual report SWEDEHEART 2012 [Internet]. 2013. [cited 2016 Sep 1]. Available from: http://www.ucr.uu.se/swedeheart/index.php/dokument-sh/doc_download/253-swedeheart-annual-report-2012-english
   Google Scholar
• Wilson PWF, D’Agostino R, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125:695–703.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753.
   PubMed Web of Science ®Google Scholar
• Lothgren M, Danese M, Taylor B, et al. Avoiding overestimation in annualization of event risk from risk functions for use in economic modeling. Value Health. Elsevier. 2016;18:A338.
   Web of Science ®Google Scholar
• Wong B, Kruse G, Kutikova L, et al. Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature. Clin Ther. 2016;38:1696–1709.
   PubMed Web of Science ®Google Scholar
• Villa G, Wong B, Kutikova L, et al. Prediction of cardiovascular risk in patients with familial hypercholesterolemia. Eur Heart J. 2017;3:274–280.
   Google Scholar
• Cholesterol Treatment Trialists Collaboration (CTTC). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435.
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum-cholesterol concentration lower risk of ischemic-heart-disease. Br Med J. 1994;308:367–373.
   PubMed Web of Science ®Google Scholar
• Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97:946–952.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005;46:1855–1862.
   PubMed Web of Science ®Google Scholar
• Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with Ezetimibe/Simvastatin post-acute coronary syndrome. J Am Coll Cardiol. 2016;67:353–361.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. Massachusetts Medical Society. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472.
   Web of Science ®Google Scholar
• Danese M, Taylor B, Lothgren M. Rates of Cardiovascular Events in Patients Receiving High-Intensity Statin Therapy in the United Kingdom. Poster Presentation at the American Heart Association Scientific Session; Orlando, Florida; November 7–11; 2015.
   Google Scholar
• National Statistical Institute (Национален статистически институт). Mortality by causes, sex and age [Internet]. 2015. [cited 2016 Jan 13]. Available from: http://www.nsi.bg/en/content/5625/mortality-causes-sex-and-age
   Google Scholar
• National Health Insurance Fund (Национална Здравноосигурителна Каса [НЗОК]). Ordinance No. 10 from 24. 03.2009 for the conditions and order for payment of medicinal products under article 262, al 6, p. 1 and p. 2 [Internet]. [cited 2016 Jan 13]. Available from: http://www.nhif.bg/web/guest/67
   Google Scholar
• National Council on Prices and Reimbursement of Medicinal Products (Национален съвет по цени и реимбурсиране на лекарствените продукти). Appendix No.1 of Positive Drug List [Internet]. 2015. [cited 2016 Jan 13]. Available from: http://www.ncpr.bg/bg/%25D1%2580%25D0%25B5%25D0%25B3%25D0%25B8%25D1%2581%25D1%2582%25D1%2580%25D0%25B8/%25D0%25BF%25D1%2580%25D0%25B8%25D0%25BB%25D0%25BE%25D0%25B6%25D0%25B5%25D0%25BD%25D0%25B8%25D0%25B5-1-%25D0%25BF%25D0%25BB%25D1%2581
   Google Scholar
• IMS. IMS medical index MAT 08/2015. Danbury, Connectitcut; 2015.
   Google Scholar
• National Health Insurance Fund (Национална Здравноосигурителна Каса [НЗОК]). Ordinance No. 40 from 24. 11. 2004 for defining the basic package of healthcare activities, guaranteed by the budget of NHIF [Internet]. [cited 2016 Jan 13]. Available from: http://www.nhif.bg/web/guest/67
   Google Scholar
• Briggs A, Claxton K, Sculpher M, et al. Decision modelling for health economic evaluation. Oxford, New York: Oxford University Press; 2006.
   Google Scholar
• Curtis JR, Schabert VF, Harrison DJ, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clinical Ther. Elsevier. 2014;36:996–1004.
   PubMed Web of Science ®Google Scholar
• Gitlin M, Meridor N, Whang J, et al. Cost per effectively treated patient with evolocumab 140mg, Alirocumab 75/150mg among patients using PCSK9 inhibitor therapy. J Clin Lipidol. Elsevier. 2016;10:685–686.
   Google Scholar
• Ministry of Health (Министерство на здравеопазването). Committee on Health Technology Assessment. Report RD-422. Repatha 140 mg solution for injection. [Internet]. 2016 [cited 2016 Sep 2]. Available from: http://ncphp.government.bg/index.php?option=com_content&view=article&id=1451&catid=369&Itemid=638&lang=bg
   Google Scholar
• WHO. Cost effectiveness and strategic planning (WHO-CHOICE) [Internet]. 2015. [cited 2016 Jul 12]. Available from: http://www.who.int/choice/costs/CER_levels/en/
   Google Scholar
• National Council on Prices and Reimbursement of Medicinal Products (Национален съвет по цени и реимбурсиране на лекарствените продукти). Methodological guidelines to documents presented to evaluate the efficacy, therapeutic effectiveness, safety and pharmacoeconomic indicators of medicinal products when applying for maintaining reimbursement status in the Positive Drug List [Internet]. 2015. [cited 2016 Jul 20]. Available from: http://www.ncpr.bg/images/News/Ukazania_NCPR_reimb_status.pdf
   Google Scholar
• Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the World of Vaccines. PharmacoEconomics. 2014;32:525–531.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–124.
   PubMed Web of Science ®Google Scholar
• Ochalek J, Lomas J, Claxton K. Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data [Internet]. York; 2015 [cited 2016 Jul 12]. p. 50. Available from: http://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP122_cost_DALY_LMIC_threshold.pdf
   Google Scholar
• European Commission Public Health. Eurobarometer - Patient safety and quality of care, Bulgaria [Internet]. 2013. [cited 2016 Aug 12]. Available from: http://ec.europa.eu/health/patient_safety/eurobarometers/ebs_411_en.htm
   Google Scholar
• European Commission Public Health. Equity of access to health care services, Proportion of people with self-declared unmet needs for health care services due to either financial barriers, waiting times or travelling distances [Internet]. European Core Health Indicators (ECHI). 2014. [cited 2016 Aug 12]. Available from: http://ec.europa.eu/health/social_determinants/indicators/index_en.htm
   Google Scholar
• Koren M, Sabatine M, Giugliano R. Long-term low-density lipoprotein cholesterol–lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label osler-1 extension study. JAMA Cardiol. 2017;2:598–607.
   Web of Science ®Google Scholar